Key Takeaways Black Diamond is advancing silevertinib for EGFR-mutant NSCLC and glioblastoma.BDTX outlicensed BDTX-4933 to Servier for $70M, streamlining focus on silevertinib.Cash reserves of$142.8M are expected to fund operations into Q4 2027.Black Diamond Therapeutics, Inc. ((BDTX) is developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s lead pipeline candidate is silevertinib.Silevertinib is a brain penetrant, fourth-generation epidermal growt ...